United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - ferric carboxymaltose - solution for injection - 50mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron (iii) - solution for injection/infusion - 20 milligram(s)/millilitre - iron trivalent, oral preparations; saccharated iron oxide

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron (iii) - hydroxide sucrose complex - solution for injection/infusion - 20  milligram(s)/millilitre - iron trivalent, oral preparations; saccharated iron oxide

United States - English - NLM (National Library of Medicine)

fresenius medical care holdings, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 20 mg in 1 ml - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and

United States - English - NLM (National Library of Medicine)

american regent, inc. - iron sucrose (unii: fz7nyf5n8l) (ferric cation - unii:91o4lml611) - ferric cation 20 mg in 1 ml - venofer is indicated for the treatment of iron deficiency anemia (ida) in patients with chronic kidney disease (ckd). - known hypersensitivity to venofer. risk summary published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see data) . available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage. there are risks to the mother and fetus associated with untreated ida in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see clinical considerations) . animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - iron dextran (unii: 95hr524n2m) (ferric cation - unii:91o4lml611) - ferric cation 50 mg in 1 ml - intravenous or intramuscular injections of infed are indicated for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. hypersensitivity to the product. all anemias not associated with iron deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 4170 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions:- when oral iron preparations are ineffective or cannot be used - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 2085 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions:- when oral iron preparations are ineffective or cannot be used - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 834 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions:- when oral iron preparations are ineffective or cannot be used - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 417 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions: - when oral iron preparations are ineffective or cannot be used; - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.